Background Osimertinib is a potent, third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study …

The use of biomarkers as early warning systems in the evaluation of disease risk has
increased markedly in the last decade. Biomarkers are indicators of typical biological …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

PURPOSE Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with
cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung …

The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

Single-agent osimertinib is the standard of care for the first-line treatment of
advancedEGFR+ NSCLC and remained the only marketed third-generation EGFR tyrosine …

Osimertinib is a third-generation, irreversible oral EGFR-tyrosine kinase inhibitor), that
potently inhibits EGFR-tyrosine kinase inhibitor-sensitizing mutations and T790M resistance …

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment prolongs
the survival of lung cancer patients harbouring activating EGFR mutations. However …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for
80–85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …